[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuroendocrine-neoplasms-tumours\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuroendocrine-neoplasms-tumours":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,71,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100624018","phase-2-study-to-assess-the-safety-and-effectiveness-of-novel-radiopharmaceutical-terbium-161-dotatate-in-metastatic-neuroendocrine-tumors-100624018",false,"NCT07404176","Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors","Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors: Assessment of Safety and Efficacy","TENET","Inclusion Criteria:\n\n* Male or female, age greater than 18 years\n* Histopathological diagnosis of well-differentiated GEP-NET\n* Positive Ga-68-DOTANOC PET\u002FCT, Krennings score \\>\u002F=3\n* Locally advanced\u002Finoperable disease or metastatic disease\n* Patient who have shown disease progression with Lu-177 DOTATATE PRRT\n* Karnofsky performance-status score of at least 60 or ECOG performance status \\\u003C\u002F=2\n* Life expectancy greater than 6 months\n\nExclusion Criteria:\n\n* Serum creatinine level of more than 1.6 mg\u002Fdl or a creatinine clearance of less than 50 ml\u002Fmin\n* Hemoglobin level of less than 8.0 g per deciliter\n* Red blood cell count less than 300,000\u002Fcubic millimeter\n* White cell count of less than 2000 per cubic millimeter\n* Platelet count of less than 75,000 per cubic millimetre\n* Total bilirubin level of more than 3 times the upper limit of the normal range\n* Serum albumin level \\> 3.0 g\u002Fdl\n* Pregnancy and Lactation\n* Patients with concurrent malignancies","ALL","18 Years","70 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Gastro-enteropancreatic Neuro-endocrine tumors (GEP-NETs) are rare slow-growing cancers which commonly involve the abdominal organs like liver, stomach, intestines and pancreas. Their incidence has been documented to have increased over the last decade, thus resulting in treatment options being developed to treat these cancers. These cancers spread commonly to the liver, followed by lungs, bones and other sites. Depending on the extent of disease seen on scan, treatment is planned. Patients are advised Peptide Receptor Radionuclide Therapy (PRRT), which is the current standard of treatment for metastatic GEP-NETs. Radio-isotopes labeled to octreotide analogs bind to somatostatin receptors on surface of cancer cells and deliver radiation to the cancer cells when injected into the body. Lu-177 (Lutetium-177) is one such radioisotope which has been used for tagging to the octreotide and is known as Lu-177 DOTATATE PRRT, which is now routinely used in clinical practice. Terbium-161 is another radioisotope which can be labeled to octreotide and used for PRRT. It has advantages over Lu-177 such that it specifically reaches the tumor sites and does not affect the surrounding normal cells, due to its higher penetrating capacity and shorter range of travel. This will benefit patients as the effectiveness of PRRT will be higher with lesser side effects. However, the investigators can only do this by performing a study. Response to treatment can be evaluated by performing scans and side effects, if any can be studied by performing blood tests.",[28,29,30],"Neuroendocrine Neoplasms (Tumours)","Neuroendocrine Tumors","Metastatic Neuroendocrine Tumors",[32,33,34],"Terbium 161","metastatic NET","DOTATATE","RECRUITING","2026-02-04",{"date":38,"type":39},"2026-02-11","ACTUAL",{"date":41,"type":22},"2026-03-01",{"date":43,"type":22},"2029-02-28",{"name":45,"class":46},"Tata Memorial Hospital","OTHER_GOV",2,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100614433","phase-2-clinical-study-of-adjuvant-surufatinib-therapy-for-postoperative-high-risk-neuroendocrine-tumors-based-on-the-ninth-edition-of-the-ajcc-staging-system-100614433","NCT07279532","Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System","Inclusion Criteria:\n\n1. Provide written informed consent and voluntarily participate in the study.\n2. Aged 18-80 years, male or female.\n3. Confirmed as Stage III NET G1\u002FG2 or any-stage NET G3 after surgical treatment.\n4. Other postoperative NET patients deemed by the investigator to have high-risk factors.\n5. Adequate organ function meeting the following criteria (no use of any blood components, cell growth factors, or corrective drugs within 14 days prior to the first dose of the study drug): (i) Absolute Neutrophil Count (ANC) ≥1.5×10⁹\u002FL; (ii) Platelets ≥100×10⁹\u002FL; (iii) Hemoglobin ≥8 g\u002FdL; (iv) Total Bilirubin ≤1.5 × ULN; ALT and AST ≤2.5 × ULN (or ≤5 × ULN if liver metastases are present); (v) Serum Creatinine ≤1.5 × ULN or Creatinine Clearance \\>60 mL\u002Fmin (Cockcroft-Gault formula).\n6. Female subjects of childbearing potential must have a negative serum pregnancy test within 72 hours before the first study drug dose and use effective contraception during the study and for at least 3 months after the last dose. Male subjects with female partners of childbearing potential must use effective contraception during the study and for 3 months after the last dose.\n\nExclusion Criteria:\n\n1. Major surgery, open biopsy, or significant trauma within 28 days prior to the first dose.\n2. History of severe or poorly controlled interstitial lung disease.\n3. Poorly controlled hypertension (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg) despite antihypertensive medication.\n4. Poorly controlled cardiovascular diseases, including but not limited to:\n\n   (i)NYHA Class II or higher heart failure; (ii) Unstable angina; (iii) Myocardial infarction within the past year; (iv) Clinically significant supraventricular or ventricular arrhythmias poorly controlled with or without intervention.\n5. Significant bleeding tendency or clinically significant bleeding within 3 months prior to the first dose (e.g., gastrointestinal bleeding, hemorrhagic gastric ulcer, vasculitis).\n6. Arterial\u002Fvenous thrombotic events within 6 months prior to the first dose (e.g., transient ischemic attack, cerebral hemorrhage, cerebral infarction, deep vein thrombosis, pulmonary embolism). Superficial vein thrombosis may be enrolled if deemed eligible by the investigator.\n7. Concurrent active malignancy requiring treatment, except for adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix.\n8. Pregnancy or lactation.\n9. Any other condition deemed by the investigator to potentially lead to study discontinuation (e.g., severe comorbid illnesses, abnormal laboratory values, psychosocial issues).","80 Years",{"count":56,"type":22},35,[25],"The following issues warrant in-depth investigation: further refinement of staging by primary tumor site, the increasing prognostic weight of T classification, risk assessment for lymph node metastasis and postoperative recurrence\u002Fdistant metastasis, and whether NET G3 with poor prognosis requires more aggressive postoperative intervention. This study plans to enroll patients classified as Stage III according to the AJCC 9th Edition staging system, including NET G1\u002FG2 and all G3 patients, for a clinical trial on postoperative adjuvant therapy.",[28],"NOT_YET_RECRUITING","2025-12-09",{"date":63,"type":39},"2025-12-12",{"date":65,"type":22},"2026-01-01",{"date":67,"type":22},"2030-12-31",{"name":69,"class":70},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":88,"leadSponsor":90,"locationsCount":4},"100598905","phase-2-the-efficacy-of-trop2-adc-in-advanced-extrapulmonary-high-grade-neuroendocrine-neoplasms-failure-of-standard-therapy-100598905","NCT07077564","The Efficacy of TROP2-ADC in Advanced Extrapulmonary High-Grade Neuroendocrine Neoplasms Failure of Standard Therapy","A Single-Center, Single-Arm, Phase II Clinical Trial of TROP2-ADC in Patients With Advanced Extrapulmonary High-Grade Neuroendocrine Tumors Refractory to Standard Therapy","SKB264-II-NEN","Inclusion Criteria:\n\n1. Provide written informed consent and voluntarily participate in the study.\n2. Aged 18-75 years, male or female.\n3. Histologically or cytologically confirmed diagnosis of one of the following:\n\n   Metastatic neuroendocrine carcinoma (NEC) Neuroendocrine tumor (NET) Grade 3 (G3) Mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) with \\>30% neuroendocrine component.\n4. Progression after at least one prior line of systemic therapy.\n5. ECOG Performance Status of 0 or 1.\n6. Life expectancy ≥3 months.\n7. At least one measurable lesion per RECIST 1.1 at baseline:\n8. Lesions must not have received prior local therapy (e.g., radiotherapy). Lesions within prior radiotherapy fields are acceptable if progression is documented.\n9. Adequate organ function (no blood products\u002Fgrowth factors within 14 days prior):\n\n   * Absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL\n\n     * Platelets ≥100×10⁹\u002FL ③Hemoglobin ≥8 g\u002FdL ④Total bilirubin ≤1.5 × ULN ⑤ALT\u002FAST ≤2.5 × ULN (≤5 × ULN if liver metastases present) ⑥Serum creatinine ≤1.5 × ULN or creatinine clearance \\>60 mL\u002Fmin (Cockcroft-Gault formula).\n\n9\\. Contraception requirements:\n\nFemales of childbearing potential:\n\nNegative serum pregnancy test within 72 hours prior to dosing. Use highly effective contraception (e.g., IUD, oral contraceptives, condoms) during and for ≥3 months after last dose.\n\nMales with fertile partners:\n\nUse effective contraception during and for ≥3 months after last dose.\n\nExclusion Criteria:\n\n* (1) Active CNS metastases and\u002For carcinomatous meningitis.\n\n  * Exception: Subjects with treated brain metastases may enroll if: Stable for ≥28 days prior to study initiation, Off steroids for brain metastases ≥28 days. Note: Carcinomatous meningitis excluded regardless of stability.\n\n    (2) Major surgery, open biopsy, or significant trauma within 28 days prior to first dose.\n\n    (3) History of severe interstitial lung disease (ILD) with inadequate control. (4) Uncontrolled hypertension (SBP ≥140 mmHg or DBP ≥90 mmHg despite antihypertensive therapy).\n\n    (5) Poorly controlled cardiovascular disease, including:\n    1. NYHA Class II+ heart failure\n    2. Unstable angina\n    3. Myocardial infarction within 1 year\n    4. Clinically significant supraventricular\u002Fventricular arrhythmias refractory to intervention (6) Clinically significant bleeding within 3 months prior to first dose (e.g., GI bleeding, hemorrhagic gastric ulcer, vasculitis). (7) Arterial\u002Fvenous thromboembolic events within 6 months prior to first dose (e.g., CVA, TIA, cerebral hemorrhage, DVT, PE).Exception: Superficial thrombosis per investigator assessment.\n\n       (8) Active other malignancy requiring therapy. Exceptions: Non-melanoma skin cancer in situ with curative treatment.\n\n       (9)Pregnancy or lactation. (10)Other factors potentially leading to premature discontinuation per investigator judgment: Severe comorbidities (including psychiatric), Critical lab abnormalities, Social\u002Ffamilial factors compromising safety\u002Fdata integrity (11)TROP2-targeted agents, ADC drugs (e.g., 8201)Topoisomerase I inhibitor-containing ADCs (12)Live vaccination within 30 days prior to first dose or planned during study.\n\n       (13)Requirement for strong CYP3A4 inhibitors\u002Finducers within 2 weeks prior to first dose or during study.\n\n       (14) Palliative radiotherapy to known metastatic sites within 2 weeks prior to first dose.\n\n       (15)Systemic anti-infective therapy within 1 week prior to first dose. Severe ocular conditions including: (16)Dry eye syndrome, Meibomian gland dysfunction, Blepharitis, Corneal disease delaying healing (17)Other exclusionary conditions per investigator assessment.","75 Years",{"count":56,"type":22},[25],"The response rate to second-line or later therapies for extrapulmonary high-grade neuroendocrine neoplasms (NENs) remains low, with no established standard treatment regimen. Patients exhibit short survival periods, with median overall survival ranging from 5.1 to 18 months, representing a significant unmet clinical need. Sacituzumab govitecan has been evaluated in multiple clinical trials including OptiTROP-Breast01, KL264-01, OptiTROP-Lung01, OptiTROP-Lung03, and SKB264-Ⅱ-06. Current results consistently indicate promising efficacy of Sacituzumab govitecan in lung cancer, breast cancer, and cervical cancer. Notably, data presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting revealed that TROP2 is highly expressed in neuroendocrine tumors, and its expression is significantly associated with poor prognosis. This suggests TROP2-directed antibody-drug conjugates (ADCs) may demonstrate promising therapeutic potential in NENs.\n\nResearch Objective:To evaluate the efficacy of Sacituzumab govitecan in patients with advanced extrapulmonary neuroendocrine neoplasms who have progressed on standard therapies.",[28],"2025-07-20",{"date":86,"type":39},"2025-07-22",{"date":84,"type":22},{"date":89,"type":22},"2028-07-20",{"name":69,"class":70},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100387420","mobile-application-to-collect-pro-data-in-net-patients-100387420","NCT04324502","Mobile Application to Collect PRO Data in NET Patients","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of a NET\n* Planned treatment for NET\n* Able to give informed consent\n* Able to understand the language of the questionnaires\n* A minimum expected survival of 6 months\n* All performance status is acceptable\n* 18 years of age or over\n\nExclusion Criteria:\n\n* Concurrent malignancies for which they are undergoing treatment\n* No smartphone \u002F device\n* Any physical, psychological or comprehension problems that prevents completion of questionnaires.",{"count":98,"type":22},2000,"OBSERVATIONAL","Observational trial to assess the feasibility of monitoring patient reporting symptoms via mobile devices",[28],"2020-11-05",{"date":104,"type":39},"2020-11-09",{"date":106,"type":39},"2020-07-20",{"date":108,"type":22},"2026-07",{"name":110,"class":70},"King's College Hospital NHS Trust",1]